Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation (NYSE: SYK) is described as a global leader in medical technologies, with a focus on MedSurg, Neurotechnology and Orthopaedics. The news flow around Stryker reflects this broad footprint, covering topics from product launches and clinical technology updates to quarterly financial results, leadership changes and portfolio transactions.
Investors following SYK news will see regular announcements of earnings results, including detailed third quarter and other period operating updates furnished via press releases and Form 8-K filings. These communications typically discuss segment performance in MedSurg and Neurotechnology and Orthopaedics, along with commentary from management on sales trends and margins.
Stryker also issues news about product innovation in orthopaedics and trauma. Recent examples include the launch of the FDA-cleared Incompass Total Ankle System for patients with end-stage ankle arthritis and updates on trauma offerings such as the Pangea platform and T2 Alpha system, which are designed to support complex fracture management. These announcements often coincide with major medical society meetings and highlight design goals and clinical use cases.
Corporate and strategic developments appear frequently in Stryker’s news stream. The company has reported leadership changes, such as the appointment of a President and Chief Operating Officer and the promotion of a new Group President, Orthopaedics. It has also communicated portfolio moves, including references to the divestiture of its spinal implant business and news that VB Spine LLC acquired Stryker’s U.S. spine implant business and a spine implant manufacturing facility in Cestas, France.
In addition, Stryker announces investor events, such as upcoming earnings webcasts, participation in healthcare conferences and Investor Day presentations. For investors and healthcare professionals, the SYK news page provides a centralized view of these financial, strategic and product-related updates, offering context on how the company’s medical technologies and corporate decisions evolve over time.
Stryker (NYSE:SYK) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will release its Q3 2025 earnings press release at 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET.
The financial results will cover the quarter ending September 30, 2025. Investors can access the webcast through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.
Stryker (NYSE:SYK) announced the launch of its Incompass™ Total Ankle System at the 2025 AOFAS Annual Meeting in Savannah, Georgia. The FDA-cleared system is designed for patients with end-stage ankle arthritis, featuring an innovative implant with an enhanced instrument platform.
The system builds on Stryker's legacy designs, Infinity and Inbone, which have demonstrated five-year survivorship rates of 98% or higher. Key features include 3D-printed porous metal components for early bony ingrowth, intraoperative flexibility, and reduced procedural complexity. The development leveraged SOMA technology and analysis of over 80,000 Prophecy scans and 100,000 total ankle cases.
Stryker (NYSE:SYK), a leading medical technology company, has announced it will host an Investor Day on November 13, 2025, at 2:30 p.m. Eastern Time. The event will take place in Mahwah, New Jersey.
Investors and interested parties can access the event through a live audio webcast on Stryker's website. For those unable to attend live, a replay of the session will be made available in the Investor Relations section of www.stryker.com.
Stryker (NYSE:SYK), a leading medical technology company, announced its participation in the upcoming 2025 Wells Fargo Securities Healthcare Conference. The event will take place at the Encore Boston Harbor on September 4, 2025.
Andy Pierce, Group President of MedSurg and Neurotechnology, and Jason Beach, Vice President of Finance and Investor Relations, will engage in a Fireside Chat at 2:15 PM ET. Investors can access both the live webcast and replay through Stryker's website.
Stryker (NYSE:SYK) has announced a quarterly dividend declaration of $0.84 per share. The dividend will be paid on October 31, 2025, to shareholders of record as of September 30, 2025. This dividend represents a 5.0% increase compared to the previous year, while remaining consistent with the last quarter's payout.
Stryker (NYSE:SYK) reported strong Q2 2025 results with net sales increasing 11.1% to $6.0 billion. The company achieved significant organic growth of 10.2%, driven by a 9.7% increase in unit volume and 0.5% from higher prices. Adjusted EPS grew 11.4% to $3.13, while adjusted operating income margin improved 110 basis points to 25.7%.
The MedSurg and Neurotechnology segment led growth with 17.3% increased sales to $3.8 billion, while Orthopaedics segment sales grew 2.0% to $2.2 billion. Based on strong performance, Stryker raised its 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted EPS of $13.40 to $13.60.
Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill® Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.
The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.
Stryker (NYSE:SYK) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025. The company will release its Q2 2025 earnings press release at approximately 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.
Stryker (NYSE:SYK) has received FDA 510(k) clearance for its Incompass® Total Ankle System, designed for patients with severe ankle joint conditions. The system integrates technologies from Stryker's Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement.
The innovative platform incorporates Adaptis® Boney Ingrowth Technology and is informed by data from over 85,000 CT scans and 100,000 clinical cases. Built using the SOMA platform and Prophecy Surgical Planning System, Incompass features redesigned instrumentation, improved alignment systems, and streamlined surgical workflow to enhance procedural efficiency and patient-specific care.